Vir Biotechnology Inc. (NASDAQ: VIR) reported Q3 EPS of ($1.17), $0.33 worse than the analyst estimate of ($0.84). Revenue for the quarter came in at $240 thousand versus the consensus estimate of $2.11 million.

2025 Financial Guidance

Based on current operating plans, the Company expects its cash, cash equivalents and investments to fund operations into mid-2027.

For earnings history and earnings-related data on Vir Biotechnology Inc. (VIR) click here.